Iranian journal of Pediatric Hematology and Oncology
Iranian journal of Pediatric Hematology and Oncology
Iran J Ped Hematol Oncol
Medical Sciences
http://ijpho.ssu.ac.ir
1
admin
2008-8892
2228-6993
8
7
14
8888
13
en
jalali
1401
7
1
gregorian
2022
10
1
12
4
online
1
fulltext
en
Visual and Auditory Complications during Deferasirox Therapy in Beta-thalassemia
قلب
Heart
پژوهشي
Research
<div style="border:double windowtext 1.5pt; padding:1.0pt 4.0pt 1.0pt 4.0pt"><span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">Background: </span></span></b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">Deferasirox is an oral iron chelator widely used to treat iron overload in patients with transfusion-dependent β-thalassemia. This study investigated the prevalence of visual and auditory complications caused by deferasirox. </span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">Materials and Methods: </span></span></b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">This cross-sectional study included 156 patients aged less than 18 years with transfusion-dependent β-thalassemia and deferasirox iron chelator consumption admitted to the 17 Shahrivar Hospital and the Besat Clinic in Rasht, Iran. All the patients were examined for visual and auditory complications caused by deferasirox in 2019. A checklist of the patients' demographical and clinical data was recorded. Data analysis was done with SPSS and reported by descriptive statistics. Then, Fisher's exact test was performed to examine the association between visual and auditory disorders and the use of deferasirox in terms of disease-related variables including age, sex, age of onset of using chelator, drug use duration, drug dosage, and mean 6-months serum ferritin levels (P <0.05 as the significance level).</span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">Results: </span></span></b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">Of a total of 156 patients, 103 (66%) were female and 56 (35.9%) were 20-30 years of age. The prevalence of visual acuity change was 0.6%, and the prevalence of sensorineural hearing loss was 1.3%. There was only one female with the visual disorder decreasing to 9/10 and with a dose of 31-40 mg/kg/day with an average of 1000-2500 ng/ml six-month ferritin. Also, two females with hearing impairment were confirmed with a dose of ≤30 mg/kg/day, and an average of ≤1000 ng/ml six-month ferritin. The Fisher's exact test results showed no significant relationship between visual and auditory disorders with the use of deferasirox in terms of disease-related variables (p>0.05).</span></span></span></span></span><br>
<span style="font-size:11pt"><span style="line-height:normal"><span sans-serif="" style="font-family:Calibri,"><b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">Conclusion: </span></span></b><span style="font-size:10.0pt"><span new="" roman="" style="font-family:" times="">The study's findings showed no significant relationship between visual and auditory disorders with deferasirox consumption. The results indicated the safety of deferasirox regarding visual and auditory side effects. More studies are required to confirm the findings.</span></span></span></span></span></div>
Beta-thalassemia, Deferasirox, Hearing loss, Iron chelator, Visual acuity
229
239
http://ijpho.ssu.ac.ir/browse.php?a_code=A-10-908-1&slc_lang=en&sid=1
Parastoo
Poosheshdoost
p.med23@gmail.com
0000-0002-9772-0404
No
Pediatric Disease Research Center, Guilan University of Medical Science, Rasht, Iran
Pediatric Disease Research Center, Guilan University of Medical Science, Rasht, Iran
Niloofar
Faraji
niloofarfaraji.sci@gmail.com
0000-0001-5796-7157
No
Gastrointestinal and Liver disease Research Center, Guilan University of Medical science, Rasht, Iran
Gastrointestinal and Liver disease Research Center, Guilan University of Medical science, Rasht, Iran
Tahereh
Zeinali
tarane.zeinali@gmail.com
0000-0002-7510-6251
No
Gastrointestinal and Liver disease Research Center, Guilan University of Medical science, Rasht, Iran
Gastrointestinal and Liver disease Research Center, Guilan University of Medical science, Rasht, Iran
Adel
Baghersalimi
baghersalimi498@yahoo.com
0000-0002-1279-5379
No
Pediatric Disease Research Center, Guilan University of Medical Science, Rasht, Iran
Pediatric Disease Research Center, Guilan University of Medical Science, Rasht, Iran
Aye
Miremarati
ayemiremarati@gmail.com
No
Pediatric Disease Research Center, Guilan University of Medical Science, Rasht, Iran
Pediatric Disease Research Center, Guilan University of Medical Science, Rasht, Iran
Bahram
Darbandi
bahram.darbandi.oncology@gmail.com
0000-0001-6100-6332
Yes
Pediatric Disease Research Center, Guilan University of Medical Science, Rasht, Iran
Pediatric Disease Research Center, Guilan University of Medical Science, Rasht, Iran